Skip to content

TrakCare

This page tracks TrakCare from the official InterSystems UK healthcare product set.

Official InterSystems Positioning

InterSystems positions TrakCare as a flexible EHR and healthcare information system using a unified user interface, code base, and data platform for patient records and interoperability.

Role in the Portfolio

TrakCare is the established EHR / healthcare information system family. It is relevant to NHS EPR replacement, hospital digital transformation, patient-record workflow, and interoperability topics where TrakCare is named.

Evidence Status

Confidence is high for vendor positioning. UK NHS examples in this wiki include North Tees and Hartlepool and The Royal Orthopaedic Hospital, but adoption and outcome claims need trust, procurement, and implementation evidence on the relevant example pages.

Scotland and Wales now have separate UK connectivity context: Scotland evidence is TrakCare / Ensemble oriented with Public Health Scotland and NHS Shetland support, and Wales evidence is strongest for all-Wales LIMS / TrakCare Lab Enterprise through board and procurement sources. Neither should be converted into a GP Connect claim.

International primary-healthcare and community-health evidence is tracked separately so country presence is not confused with PHC implementation. Current public evidence supports Gateway Health community-health use in Australia, Victorian community-health TrakCare use, Chile SSMS APS / referral-workflow relevance, and reported DHAMAN primary-healthcare-centre / outpatient-care use with current DHAMAN network context.

Follow-up Evidence

  • Current TrakCare module documentation, implementation guides, and regional availability.
  • Current formal customer-side and procurement evidence for PHC/community-health deployments, especially Gateway Health, Victoria provider-level scope, named Chile APS live status, DHAMAN TrakCare primary-source scope, and Qatar current status.
  • UK procurement and contract evidence for named deployments.
  • Go-live, support, and clinical-safety artefacts where public.
  • Independent evidence for EPR outcomes.